Christina Wenglen
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Antifibrotic effects of specific targeting of the 5-hydroxytryptamine 2B receptor (5-HT2BR) in murine models and ex vivo models of scleroderma skin.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: May 06, 2024
Pulmonary 5-HT2B receptor expression in fibrotic interstitial lung diseases.
Journal: Acta histochemica
Published: November 01, 2022
Targeting serotonin receptor 2B inhibits TGFβ induced differentiation of human vascular smooth muscle cells.
Journal: European journal of pharmacology
Published: October 07, 2022
Pathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases.
Journal: International journal of molecular sciences
Published: November 30, 2020
Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT2B receptor antagonists in vitro - a potential pathway affecting proliferation.
Journal: Scientific reports
Published: September 20, 2017
Effects of 5-Hydroxytryptamine Class 2 Receptor Antagonists on Bronchoconstriction and Pulmonary Remodeling Processes.
Journal: The American journal of pathology
Published: September 15, 2017
Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus.
Journal: PloS one
Published: November 05, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026